Dr. Nathalie Grandvaux
M.Sc. Eng Biochemistry, INSA Lyon
DEA, Biochemistry, INSA Lyon
PhD Molecular and Cellular Biology, Université Grenoble, France
Department of Biochemistry and Molecular Medicine,
Faculty of Medicine
Université de Montréal
Associate scientific director - students and postdoctoral affairs,
Centre de recherche du Centre Hospitalier de l'Université de Montréal.
Past-president and co-founder Canadian Society for Virology
Co-founder and Co-director (2020-2022) Réseau Québécois COVID - Pandémie/Quebec COVID - pandemic Network
Dr. Nathalie Grandvaux was initially trained as an engineer in Biochemistry at the « Institut National des Sciences Appliquées » in Lyon, France in 1993. In 1999, she obtained a PhD in Molecular and Cellular Biology from the University of Grenoble under the supervision of Pr. P.V. Vignais and Dr. M.C. Dagher. She was interested in the structural and functional analysis of the NOX2 cytosolic activating factor p40phox. She joined the laboratory of Dr. J. Hiscott at McGill University as a post-doctoral fellow in 2000 to perform research on the NF-kB and IRF transcription factors in various virus infections (HTLV-1, HIV, VSV, Sendai virus) with a particular emphasis on the interferon mediated antiviral response. Her work notably helped to identify the role of the IKK-related kinases, IKKi and TBK1, in the induction of type I Interferon. She was highly involved in the characterization of the regulation and function of the IRF3 transcription factor. She demonstrated the role of IRF3 in the transcription of a subset of antiviral interferon stimulated genes independently of Interferons amongst which IFIT1-3 and Arginase II involved in the metabolism of polyamines. Her work on NF-kB notably allowed to identify the role of IKKi in the activation of cRel by non-canonical mechanisms, a pathway that is relevant to breast cancer.
Recruited at Université de Montréal in 2005 at the Department of Biochemistry and Molecular Medicine and a Principal Investigator at the CRCHUM, where her lab facilities are, she is currently a full professor. She was awarded a Canada Research Chair Tier II in signaling in virus infection and oncogenesis (2005-2015). From 2015-2018 she hold a Research chair from Université de Montréal on virus signaling and oncogenesis. She pursues her research on the host mechanisms involved in the antiviral defense with a specific interest on the regulation of the Interferon-mediated antiviral defense by redox metabolism. Her group contributed seminal publication identifying the role of NADPH oxidase in the interferon-mediated antiviral defense.
She is the co-founder (2016) of the Canadian Society for Virology (CSV), a Canadian registered Not-for profit Organization aimed at fostering the interaction between Canadian virologists to strengthen virus-related research capacity in Canada. She was the first elected president of the CSV (2019-2020) and acted as past-president from 2021-2022.
In April 2020, when the COVID-19 pandemic hit Canada and Quebec, she co-founded and co-directed (2020-2022) the Quebec COVID - Pandemic Network
In 2019, she received the Paul Man Lectureship award from the Alberta Respiratory Center, University of Alberta. She also received the Mentoring Excellence Award from the Society For Redox Biology and Medicine
(SFRBM). In 2021, she received the Faculty of Medicine Dean's recognition award and the CRCHUM excellence award for contribution to the institution.